Did you know multiple sclerosis (MS) affects approximately 400,000 Americans and is the leading cause of neurological disability in young adults? As all currently available treatments for MS are given through injections or infusions many patients are anxiously awaiting an oral treatment option   more »

Laquinimod drug trials for RRMS   more »

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes, today announced an update on the continuing analysis of the company’s Phase IIb   more »

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. Food and Drug Administration (   more »

“A new oral drug for multiple sclerosis has produced promising results in clinical trials,” BBC News reported today. It said the new drug, laquinimod, improved the condition of patients with the relapse-remitting form of multiple sclerosis (MS) with few side-effects. Scans showed that patients taking a high dose of the drug   more »

Cognition Pharmaceuticals LLC today announced positive results from a Phase 2 clinical trial of C105 (l amphetamine sulfate) on 151 Multiple Sclerosis patients with documented cognitive dysfunction. In the six-week placebo-controlled study, Cognition Pharmaceuticals reported   more »

New Oral Investigational Treatment Laquinimod for Relapsing-Remitting Multiple Sclerosis at:   more »

BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (   more »

"Longer-term studies of BG00012 in larger patient populations are underway to define its place in the future of relapsing-remitting multiple sclerosis treatment. If these studies show similar relapse rate reductions with BG00012   more »

A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis If you have a spinal cord injury or multiple sclerosis, and suffer from urinary incontinence, you may qualify for the Dignity Study – a medical research study.   more »

MONTREAL -- Sustained-release fampridine improves walking and leg strength in patients with multiple sclerosis, according to data from a phase 3 study presented here at the World Congress on   more »

BioMS Medical, a biotechnology company, has announced that the independent data safety monitoring board for the company's US pivotal Phase III Maestro-03 trial of dirucotide in patients with   more »

Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis Biogen Idec today announced that enrollment is complete in the   more »

The Billings Clinic Research Center is currently conducting a research study to evaluate the safety and tolerability of a once weekly oral dosing of an investigational treatment for patients with Multiple Sclerosis. Qualified   more »

The goal of this study is to determine if an investigational oral medication is safe and effective. This treatment with the investigational oral medication is compared to treatment with a placebo. A placebo is an inactive substance or preparation used   more »